In fact, early clinical investigations suggest that combination of chemical degraders either with targeted inhibitors or with chemotherapy/other agents may represent a robust alternative path for cancer therapy: ARV-471 produced a synergistic tumoricidal effect when combined with the CDK4/6 kinase inhibitor. The gene discussed is CDK4; the disease is cancer.